INTRODUCTION: The authors report long-term outcomes in patients who received neoadjuvant chemoradiotherapy and consequently underwent hybrid oesophagectomy for oesophageal cancer (OC). AIM: To evaluate long-term outcomes in patients suffering from OC, who underwent hybrid oesophagectomy. MATERIAL AND METHODS: Our cohort consisted of patients suffering from OC, who received neoadjuvant chemoradiotherapy. Hybrid esophagectomy was performed 8-10 weeks after oncological treatment. RESULTS: Ninety-four patients underwent surgery for OC from 2011 to 2015. Histology revealed adenocarcinoma in 60.6%, squamous cell carcinoma (SCC) in 36.2%, and other type of cancer in 3.2%. Seventy-three (77.7%) patients with advanced stage (T3-4, N0-2, M0) were indicated to receive neoadjuvant chemoradiotherapy (nCRT). Trans-hiatal hybrid oesophagectomy was performed in 83 (88.3%) patients. Transthoracic hybrid oesophagectomy was performed in 11 (11.7%) patients. Histology of the resected specimens of 18 (24.7%) patients did not reveal OC, i.e. pathological complete response (pCR). In our cohort, we proved an association between occurrence of pCR and age as well as disease-free survival (DFS). The patients who presented with pCR were significantly younger - below 60 years of age (p = 0.017). They also showed significantly higher mean DFS (p = 0.004). CONCLUSIONS: Combined oesophagectomy with neoadjuvant chemoradiotherapy results in a better long-term outcome in patients suffering from oesophageal cancer. In our set of patients who underwent hybrid esophagectomy, satisfactory short-term and especially long-term results of surgical treatment for oesophageal cancer were observed.

Centre for Telemedicine Simulation and Clinical Skills Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Department of Medical Biophysics Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

Department of Oncology AGEL Hospital Nový Jičín Czech Republic

Department of Surgery 1 University Hospital Olomouc Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic

See more in PubMed

GLOBOCAN 2018: Estimated cancer incidence, mortality and prevalence worldwide in 2018. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf.

Ninomiya I, Osugi H, Fujimura T, et al. Thoracoscopic esophagectomy with extended lymph node dissection in the left lateral position: technical feasibility and oncologic outcomes. Dis Esophagus. 2014;27:159–67. PubMed

Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 2018;41:210–5. PubMed

Bonavina L, Asti E, Sironi A, et al. Hybrid and total minimally invasive esophagectomy: how I do it. J Thorac Dis. 2017;9(Suppl 8):S761–72. PubMed PMC

Meng F, Li Y, Ma H, et al. Comparison of outcomes of open and minimally invasive esophagectomy in 183 patients with cancer. J Thorac Dis. 2014;6:1218–24. PubMed PMC

Vrba R, Vrána D, Neoral Č, et al. Respiratory complications following mini-invasive laparoscopic and thoracoscopic esophagectomy for esophageal cancer. Experience in 215 patients. Videosurgery Miniinv. 2019;14:52–9. PubMed PMC

Thibault V, Alexandru L, Guillaume P. Hybrid esophagectomy. J Thorac Dis. 2019;11(Suppl 5):S723–7. PubMed PMC

Vrba R, Aujeský R, Stašek M, et al. Esophageal cancer results of surgical treatment at the Department of Surgery I at the University Hospital Olomouc. Rozhl Chir Winter. 2018;97:342–8. PubMed

Tachibana M, Kinugasa S, Hirahara N, et al. Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur J Cardiothorac Surg. 2008;34:427–31. PubMed

Gulben K, Irkin F, Yazı M, et al. Prognostic significance of number of lymph node metastasis on survival in patients with pathological T3 esophageal carcinoma. Neoplasma. 2017;64:131–5. PubMed

Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152–62. PubMed

Wlodarczyk J, Kużdżał J. Stenting as a palliative method in the management of advanced squamous cell carcinoma of the oesophagus and gastro-oesophageal junction. Videosurgery Miniinv. 2016;11:1–8. PubMed PMC

Zhang Z, Zhang H. Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patiens with esophagea lcancer. Dis Esophagus. 2017;30:1–7. PubMed

Ott K, Bader FG, Lordick F, et al. Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patient at an experienced center. Ann Surg Oncol. 2009;16:1017–25. PubMed

Wormuth JK, Heitmiler RF. Esophageal conduit necrosis. J Thorac Surg Clin. 2006;16:11–22. PubMed

Haga Y, Wada Y, Takeuchi H, et al. Prediction of anasto-motic leak and its prognosis in digestive surgery. World J Surg. 2011;35:716–22. PubMed

Atkins BZ, Shah AS, Hutcheson KA, et al. Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg. 2004;78:1170–6. PubMed

Xing XZ, Gao Y, Wang HJ, et al. Assessment of a predictive score for pulmonary complications in cancer patients after esophagectomy. World J Emerg Med. 2016;7:44–9. PubMed PMC

Raymond DP, Seder CW, Wright CD, et al. Predictors of major morbidity or mortality after resection for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database Risk Ajustment Model. Ann Thorac Surg. 2016;102:207–14. PubMed PMC

Dhungel B, Diggs BS, Hunter JG, et al. Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005-2008. J Gastrointest Surg. 2010;14:1492–501. PubMed

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84. PubMed

Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–55. PubMed

Darnton SJ, Archer VR, Stocken DD, et al. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol. 2003;21:4009–15. PubMed

Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003;9:251–60. PubMed

Lin JW, Hsu CP, Yeh HL, et al. The impact of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced squamous cell carcinoma of esophagus. J Chin Med Assoc. 2018;81:18–24. PubMed

Alnaji RM, Du W, Gabriel E, et al. Pathologic complete response is an independent predictor of improved survival following neoadjuvant chemoradiation for esophageal adenocarcinoma. J Gastrointest Surg. 2016;20:1541–6. PubMed